Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | SLC34A1 | Q06495 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MMP2 | P08253 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | FDPS | P14324 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | PGK1 | P00558 | 3/20 | 0.35 |
| ▸ | PGK2 | P07205 | 3/20 | 0.35 |
| ▸ | TYMS | P04818 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.30 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31402615 | 1.00 | CA2 (0.46) | CA2SLC34A1KDM4EMMP2THRB | |
| SCHEMBL88352 | 1.00 | — | — | |
| SCHEMBL2486859 | 1.00 | CA2 (0.46) | CA2SLC34A1KDM4EMMP2THRB | |
| Ammonia Solution, Strong SCHEMBL77057 | 0.94 | — | — | |
| SCHEMBL4275773 | 0.94 | — | — | |
| SCHEMBL7191422 | 0.94 | CA2 (0.42) | CA2SLC34A1KDM4EMMP2THRB | |
| Water SCHEMBL8386710 | 0.94 | CA2 (0.42) | CA2SLC34A1KDM4EMMP2THRB | |
| SCHEMBL8332638 | 0.94 | — | — | |
| SCHEMBL20593985 | 0.94 | — | — | |
| Phosphoric Acid SCHEMBL20815734 | 0.94 | CA2 (0.42) | CA2SLC34A1KDM4EMMP2THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11613553-B2 | Methods of preparing 1′-cyano nucleosides | GILEAD SCIENCES, INC. (US) | 2023-03-28 | — | — | US | claimed |
| EP-4118085-A2 | METHODS OF PREPARING 1'-CYANO NUCLEOSIDES | GILEAD SCIENCES, INC. (US) | 2023-01-18 | — | — | EP | claimed |
| US-20210309689-A1 | METHODS OF PREPARING 1'-CYANO NUCLEOSIDES | GILEAD SCIENCES, INC. | 2021-10-07 | — | — | US | claimed |
| WO-2021183750-A2 | METHODS OF PREPARING 1'-CYANO NUCLEOSIDES | GILEAD SCIENCES, INC. (US) | 2021-09-16 | — | — | WO | claimed |
| EP-2931709-B1 | PROCESS FOR PREPARING ASYMMETRICAL IMIDAZOLIUM SALTS | ECOLE NAT SUPERIEURE DE CHIMIE DE RENNES (FR) | 2019-10-02 | — | — | EP | claimed |
| US-9688641-B2 | Process for preparing asymmetrical imidazolium salts | ECOLE NATIONALE SUPERIEURE DE CHIMIE DE RENNES (FR) | 2017-06-27 | — | — | US | claimed |
| US-20150329494-A1 | Process for Preparing Asymmetrical Imidazolium Salts | Ecole National Superieure de Chimie de Rennes (FR) | 2015-11-19 | — | — | US | claimed |
| EP-1290747-B1 | FUEL CELLS AND FUEL CELL SYSTEMS CONTAINING NON-AQUEOUS ELECTROLYTES | IDATECH LLC (US) | 2009-02-18 | — | — | EP | claimed |
| US-7258946-B2 | Fuel cells and fuel cell systems containing non-aqueous electrolytes | IDATECH, LLC (US) | 2007-08-21 | — | — | US | claimed |
| EP-1290747-A4 | FUEL CELLS AND FUEL CELL SYSTEMS CONTAINING NON-AQUEOUS ELECTROLYTES | IDATECH LLC (US) | 2006-12-06 | — | — | EP | claimed |
| US-20030164480-A1 | For use in electrophoretic displays including transmissive, reflective and transflective displays | SIPIX IMAGING, INC. | 2003-09-04 | — | — | US | claimed |
| WO-2003058335-A2 | A NOVEL ELECTROPHORETIC DISPERSION WITH A FLUORINATED SOLVENT AND A CHARGE CONTROLLING AGENT | SIPIX IMAGING, INC. (US) | 2003-07-17 | — | — | WO | claimed |
| EP-1290747-A1 | FUEL CELLS AND FUEL CELL SYSTEMS CONTAINING NON-AQUEOUS ELECTROLYTES | IdaTech, LLC. (US) | 2003-03-12 | — | — | EP | claimed |
| US-20010053472-A1 | Fuel cells and fuel cell systems containing non-aqueous electrolytes | IDA TECH, LLC | 2001-12-20 | — | — | US | claimed |
| WO-2001093362-A1 | FUEL CELLS AND FUEL CELL SYSTEMS CONTAINING NON-AQUEOUS ELECTROLYTES | IDATECH, LLC (US) | 2001-12-06 | — | — | WO | claimed |
| EP-0502301-B1 | Composition and method of making high porosity, high strength compositions | PHILLIPS PETROLEUM CO (US) | 1995-07-26 | — | — | EP | claimed |
| EP-0502301-A1 | Composition and method of making high porosity, high strength compositions | PHILLIPS PETROLEUM COMPANY (US) | 1992-09-09 | — | — | EP | claimed |
| US-5143706-A | Calcined Mixture of Zinc Oxide, Silica and Fluoro Acid | PHILLIPS PETROLEUM COMPANY (US) | 1992-09-01 | — | — | US | claimed |
| US-5108975-A | Silica treated with fluorine fluorine containing acid solution ; utilized as catalyst support | PHILLIPS PETROLEUM COMPANY (US) | 1992-04-28 | — | — | US | claimed |
| US-5077261-A | Zince oxide, silica and fluorine-containing acid | PHILLIPS PETROLEUM COMPANY (US) | 1991-12-31 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150329494-A1 | Process for Preparing Asymmetrical Imidazolium Salts | HRH4, F12, ADH1A | CA2 266/4885SLC34A1 839/4885KDM4E 730/4885 |
| US-20210309689-A1 | METHODS OF PREPARING 1'-CYANO NUCLEOSIDES | PNP, TYMP, DUT | CA2 2966/4885SLC34A1 560/4885KDM4E 3350/4885 |
| US-11613553-B2 | Methods of preparing 1′-cyano nucleosides | PNP, TYMP, RNGTT | CA2 3026/4885SLC34A1 563/4885KDM4E 3313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.